Skip to main content

Table 1 Demographic characteristics of the study participants (primary and booster ATP immunogenicity cohorts)

From: A randomised trial to evaluate the immunogenicity, reactogenicity, and safety of the 10-valent pneumococcal non-typeable Haemophilus influenzaeprotein D conjugate vaccine (PHiD-CV) co-administered with routine childhood vaccines in Singapore and Malaysia

Primary vaccination phase

Clin group

Com group

  

N = 219

N = 218

Age

Mean age ± SD (weeks)

7.3 ± 1.35

7.3 ± 1.31

 

Age range (weeks)

6–11

6–11

Gender

Female n (%)

108 (49.3)

95 (43.6)

 

Male n (%)

111 (50.7)

123 (56.4)

Race

Asian – South East Asian heritage n (%)

217 (99.1)

217 (99.5)

 

Asian – Central/South Asian heritage n (%)

1 (0.5)

0 (0.0)

 

Asian – East Asian heritage n (%)

1 (0.5)

1 (0.5)

Booster vaccination phase

ClinCom group

ClinCom group

  

N = 115

N = 116

Age

Mean age ± SD (months)

18.8 ± 0.84

18.9 ± 0.85

 

Age range (months)

18–21

18–21

Gender

Female n (%)

59 (51.3)

48 (41.4)

 

Male n (%)

56 (48.7)

68 (58.6)

Race

Asian – South East Asian heritage n (%)

114 (99.1)

115 (99.1)

 

Asian – East Asian heritage n (%)

1 (0.9)

1 (0.9)

  1. ATP = according to protocol.
  2. Clin = group of infants from Malaysia and Singapore who received the Phase III Clinical lot of PHiD-CV in the primary vaccination phase.
  3. Com = group of infants from Malaysia and Singapore who received the Commercial lot of PHiD-CV in the primary vaccination phase.
  4. ClinCom = group of toddlers from Singapore primed with the Phase III Clinical lot of PHiD-CV who received the Commercial lot of PHiD-CV in the booster vaccination phase.
  5. ComCom = group of toddlers from Singapore primed with the Commercial lot of PHiD-CV who received the Commercial lot of PHiD-CV in the booster vaccination phase.
  6. N = number of participants.
  7. n (%) = number (percentage) of participants with the specified characteristic.
  8. SD = standard deviation.
  9. Range = minimum – maximum.